Advanced Search
Clinical Trials
Explore 635 FDA-approved clinical trials

CATEGORY


SEARCH FILTER


Recruitment Status

Study Type

Date of Registation
-



Region

Method of Allocation

Masking

Assignment

Phase



  
Results 631 - 635 of 635

A prospective, open label, 24-week trial of methylcobalamin in the treatment of diabetic polyneuropathy

Recruitment Status
Completed
Project Status
Completed
Project Description
This is an investigator-initiated, prospective, open-label study to determine the clinical and neurophysiological effects of 1,500 μgm/day of oral methylcobalamin among subjects with diabetic polyneuropathy. The primary outcome measure was the Toronto Clinical Scoring System (CSS) and secondary me . . .
Primary Sponsor
St. Luke's Medical Center - Quezon City
Study Type
Interventional
Date of Registration
10 December 2012
Date of FIrst Enrollment
09 December 2012
Region
NCR
Method of Allocation
Non-randomized
Masking
single blind (outcomes assessor)
Assignment
Single Arm
Phase
Phase IV
Sources of Monetary or Material Support
Eisai Co., Ltd.
Primary Outcomes
Toronto Clinical Scoring System (CSS)
Key Inclusion and Exclusion Criteria
1) diabetes mellitus diagnosed by elevated fasting blood sugar >126 mg/dl on two occasions or elevated glycosylated hemoglobin (HgbA1C) >6.5% and the diagnosis confirmed by a physician; 2) polyneuropathy based on the presence symptoms, signs and neurophysiologic evidence for neuropathy [10].
Countries of Recruitment
Philippines
Health Condition(s) or Problem(s) Studied
Diabetic polyneuropathy

Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine in Toddlers

Recruitment Status
Completed
Project Status
Completed
Project Description

This is a follow-up of Study JEC02 (NCT 00735644) designed to characterize the persistence of neutralizing antibodies in the five years after vaccination with Japanese encephalitis chimeric vaccine (JE-CV).

Primary Sponsor
Sanofi Pasteur
Study Type
Observational
Date of Registration
27 November 2012
Date of FIrst Enrollment
01 August 2009
Region
NCR
Assignment
Not Applicable
Phase
Phase III
Sources of Monetary or Material Support
Sanofi Pasteur
Primary Outcomes

•To describe the yearly persistence of humoral immune response to Japanese encephalitis after a single dose of JE-CV

Key Inclusion and Exclusion Criteria
Inclusion Criteria : •Provision of Informed Consent Form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations. •Subject who was vaccinated with Japanese encephalitis chimeric vaccine (JE-CV) in JEC02 . . .
Countries of Recruitment
Philippines, Thailand
Health Condition(s) or Problem(s) Studied

Encephalitis, Japanese Encephalitis


The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease

Recruitment Status
Completed
Project Status
Completed
Project Description
This is a randomized controlled, double blind trial that aims to evaluate the efficacy of methotrexate in preventing Post Molar Gestational Trophoblastic Disease (PMGTD) among patients with high-risk hydatidiform mole in our locality. Likewise, this study aims to determine the incidence of patients . . .
Primary Sponsor
University of the Philippines - Philippine General Hospital, Department of Obstetrics and Gynecology
Study Type
Interventional
Date of Registration
18 November 2013
Date of FIrst Enrollment
23 October 2013
Region
NCR
Method of Allocation
Randomized
Masking
Double Blind: The Patients, statistician, fellow a
Assignment
Parallel
Phase
Phase II/III
Sources of Monetary or Material Support
National Institutes of Health - University of the Philippines - Manila
Primary Outcomes
Criteria for the development for the postmolar gestational trophoblastic disease after administration of methotrexate or placebo: High level of βhCG more than 4 weeks post-evacuation (serum level of 20,000mlU/m), progressively increasing or plateauing hCG values at any time after evacuation (minimu . . .
Key Inclusion and Exclusion Criteria
Inclusion Criteria: Diagnosis and molar evacuation done at the Department of Obstetrics and Gynecology of the Philippine General Hospital; Patients who will undergo suction and curettage for evaluation of molar pregnancy; Histopathologically confirmed complete hydatidiform mole; Must have at least o . . .
Countries of Recruitment
Philippines, Thailand
Health Condition(s) or Problem(s) Studied
Gestational trophoblastic neoplasia Hydatidiform mole

Use of Banana leaf Dressing on Donor Site Wounds

Recruitment Status
Completed
Project Status
Ongoing
Project Description
Prospective, randomized, double-blind controlled trial comparing the healing rate, infection rate, pain score, ease of care and scar formation of banana leaf dressing versus hydro-colloid dressing. Adult patients with no uncontrolled medical condition admitted at Philippine General Hospital Burn Cen . . .
Primary Sponsor
University of the Philippines - Philippine General Hospital, Department of Surgery, Division of Burn
Study Type
Interventional
Date of Registration
22 October 2013
Date of FIrst Enrollment
24 September 2013
Region
NCR
Method of Allocation
Randomized
Masking
Double Blind - The Patient enrolled in the study w
Assignment
Parallel
Phase
Phase II
Sources of Monetary or Material Support
National Institutes of Health - University of the Philippines - Manila
Primary Outcomes
To compare the efficacy and safety of Banana Leaf Dressing with hydrocolloid dressing among patients undergoing split thickness skin graft for burn Banana Leaf Dressing (BLD) with our current standard Hydrocolloid dressing HCD with respect to: Duration of re-epithelialization, rate of infection, com . . .
Key Inclusion and Exclusion Criteria
Inclusion Criteria: Patient undergoing harvesting of skin graft one or both thigh, Surgery under general anesthesia, Given Informed consent and has accomplished a written informed consent. Exclusion Criteria: Patient with uncontrolled medical condition such as diabetes or hypertension, pregnant fem . . .
Countries of Recruitment
Philippines, Thailand
Health Condition(s) or Problem(s) Studied
Use of Banana Leaf Dressing for Split Thickness Skin Graft Donor Site Wounds

Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS 2)

Recruitment Status
Pending
Project Status
Ongoing
Project Description
This study is a randomized, open-label, eculizumab and ravulizumab-controlled, non-inferiority study. The study plans to enroll approximately 140 patients with PNH who are currently treated with either eculizumab or ravulizumab at the labeled posology. The study consists of an up to 6- week scree . . .
Primary Sponsor
Regeneron Pharmaceuticals, Inc.
Secondary Sponsor
PPD Pharmaceutical Development Philippines Corporation
Study Type
Interventional
Date of Registration
18 April 2022
Date of FIrst Enrollment
30 November -0001
Region
United States of America
Method of Allocation
Randomized
Masking
Open Label
Assignment
Parallel
Phase
Phase II/III
FDA Clinical Trial Reference (CTR) Number
2022-CT0666
Sources of Monetary or Material Support
Regeneron Pharmaceuticals, Inc.
Primary Outcomes
To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in patients with PNH who switch from eculizumab or ravulizumab therapy versus patients who continue their eculizumab or . . .
Key Inclusion and Exclusion Criteria
Key Inclusion Criteria: Diagnosis of PNH confirmed by a history of high-sensitivity flow cytometry from prior testing Treated with eculizumab or ravulizumab prior to screening visit as described in the protocol Note: Biosimilars are not permitted, unless approved by the S . . .
Countries of Recruitment
Brazil, China, Colombia, France, Germany, Greece, Hungary, Italy, Japan, Malaysia, Mexico, North Korea, Philippines, Poland, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom, United States
Health Condition(s) or Problem(s) Studied

Paroxysmal Nocturnal Hemoglobinuria


Results 631 - 635 of 635
Loading…
©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date